Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
AVD-104 yielded sustained vision improvements in patients with geographic atrophy, with no statistical difference reported in the rate of change in GA area vs. monthly avacincaptad pegol, according to a press release.
The phase 2a SIGLEC trial randomly assigned 300 patients with GA to treatment with an intravitreal dose of either 2 mg AVD-104 (Aviceda Therapeutics), a poly sialic acid-coated nanoparticle, every other month (100 patients), 1 mg AVD-104 monthly (100 patients) or 2 mg avacincaptad pegol (100 patients) for 24 months. Patients had an average age of 79 years and an average baseline